Utility of PAX8 mouse monoclonal antibody in the diagnosis of thyroid, thymic, pleural and lung tumours: A comparison with polyclonal PAX8 antibody

Histopathology

Volumn 65, Issue 4, 2014, Pages 465-472

  Toriyama, Akane ^a,b   Mori, Taisuke ^a,c   Sekine, Shigeki ^a,c   Yoshida, Akihiko ^a   Hino, Okio ^d   Tsuta, Koji ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b JUNTENDO UNIVERSITY   (Japan)

^c NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^d JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cross reactivity; Immunohistochemistry; PAX8; Thoracic tumours

Indexed keywords

MESSENGER RNA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY PAX5; MONOCLONAL ANTIBODY PAX6; MONOCLONAL ANTIBODY PAX8; POLYCLONAL ANTIBODY; POLYCLONAL ANTIBODY PAX8; TRANSCRIPTION FACTOR PAX5; TRANSCRIPTION FACTOR PAX6; TRANSCRIPTION FACTOR PAX8; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; EYE PROTEIN; HOMEODOMAIN PROTEIN; PAIRED BOX TRANSCRIPTION FACTOR; PAX5 PROTEIN, MOUSE; PAX8 PROTEIN, MOUSE; REPRESSOR PROTEIN;

ARTICLE; CANCER DIAGNOSIS; CONTROLLED STUDY; CROSS REACTION; DIAGNOSTIC TEST ACCURACY STUDY; FOLLICULAR CARCINOMA; HUMAN; HYBRIDIZATION; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN SITU HYBRIDIZATION; LARGE CELL CARCINOMA; LARGE CELL NEUROENDOCRINE CARCINOMA; LUNG ADENOCARCINOMA; LUNG CARCINOMA; LUNG TUMOR; PAPILLARY CARCINOMA; PLEURA TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; SMALL CELL CARCINOMA; SQUAMOUS CELL LUNG CARCINOMA; THYMOMA; THYROID TUMOR; TISSUE MICROARRAY; UNDIFFERENTIATED CARCINOMA; ANIMAL; COMPARATIVE STUDY; IMMUNOLOGY; LUNG NEOPLASMS; MOUSE; PLEURAL NEOPLASMS; THORACIC NEOPLASMS; THYMUS NEOPLASMS; THYROID NEOPLASMS;

ANIMALS; ANTIBODIES, MONOCLONAL; B-CELL-SPECIFIC ACTIVATOR PROTEIN; BIOLOGICAL MARKERS; EYE PROTEINS; HOMEODOMAIN PROTEINS; HUMANS; IN SITU HYBRIDIZATION; LUNG NEOPLASMS; MICE; PAIRED BOX TRANSCRIPTION FACTORS; PLEURAL NEOPLASMS; REPRESSOR PROTEINS; THORACIC NEOPLASMS; THYMUS NEOPLASMS; THYROID NEOPLASMS; TISSUE ARRAY ANALYSIS;

EID: 84911806375     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12405     Document Type: Article

References (18)

1. Laury AR, Hornick JL, Perets R et al. PAX8 reliably distinguishes ovarian serous tumours from malignant mesothelioma. Am. J. Surg. Pathol. 2010; 34; 627-635.
2. Albadine R, Schultz L, Illei P et al. PAX8 (+)/p63 (-) immunostaining pattern in renal collecting duct carcinoma (CDC): a useful immunoprofile in the differential diagnosis of CDC versus urothelial carcinoma of upper urinary tract. Am. J. Surg. Pathol. 2010; 34; 965-969.
3. Haynes CM, Sangoi AR, Pai RK. PAX8 is expressed in pancreatic well-differentiated neuroendocrine tumours and in extrapancreatic poorly differentiated neuroendocrine carcinomas in fine-needle aspiration biopsy specimens. Cancer Cytopathol. 2011; 119; 193-201.
4. Ozcan A, Shen SS, Hamilton C et al. PAX8 expression in non-neoplastic tissues, primary tumours, and metastatic tumours: a comprehensive immunohistochemical study. Mod. Pathol. 2011; 24; 751-764.
5. Laury AR, Perets R, Piao H et al. A comprehensive analysis of PAX8 expression in human epithelial tumours. Am. J. Surg. Pathol. 2011; 35; 816-826.
6. Moretti L, Medeiros LJ, Kunkalla K, Williams MD, Singh RR, Vega F. N-terminal PAX8 polyclonal antibody shows cross-reactivity with n-terminal region of PAX5 and is responsible for reports of PAX8 positivity in malignant lymphomas. Mod. Pathol. 2012; 25; 231-236.
7. Morgan EA, Pozdnyakova O, Nascimento AF, Hirsch MS. PAX8 and PAX5 are differentially expressed in B-cell and T-cell lymphomas. Histopathology 2013; 62; 406-413.
8. Lorenzo PI, Jimenez Moreno CM, Delgado I et al. Immunohistochemical assessment of PAX8 expression during pancreatic islet development and in human neuroendocrine tumours. Histochem. Cell Biol. 2011; 136; 595-607.
9. Tacha D, Qi W, Zhou D, Bremer R, Cheng L. PAX8 mouse monoclonal antibody [bc12] recognizes a restricted epitope and is highly sensitive in renal cell and ovarian cancers but does not cross-react with B cells and tumours of pancreatic origin. Appl. Immunohistochem. Mol. Morphol. 2013; 21; 59-63.
10. Lane D, Koprowski H. Molecular recognition and the future of monoclonal antibodies. Nature 1982; 296; 200-202.
11. Weissferdt A, Moran CA. PAX8 expression in thymic epithelial neoplasms: an immunohistochemical analysis. Am. J. Surg. Pathol. 2011; 35; 1305-1310.
12. Sangoi AR, Ohgami RS, Pai RK, Beck AH, McKenney JK, Pai RK. PAX8 expression reliably distinguishes pancreatic well-differentiated neuroendocrine tumours from ileal and pulmonary well-differentiated neuroendocrine tumours and pancreatic acinar cell carcinoma. Mod. Pathol. 2011; 24; 412-424.
13. Robson EJ, He SJ, Eccles MR. A panorama of PAX genes in cancer and development. Nat. Rev. Cancer 2006; 6; 52-62.
14. Morgenstern DA, Hasan F, Gibson S, Winyard P, Sebire NJ, Anderson J. PAX5 expression in nonhematopoietic tissues. Reappraisal of previous studies. Am. J. Clin. Pathol. 2010; 133; 407-415.
15. Song J, Li M, Tretiakova M, Salgia R, Cagle PT, Husain AN. Expression patterns of PAX5, c-met, and paxillin in neuroendocrine tumours of the lung. Arch. Pathol. Lab. Med. 2010; 134; 1702-1705.
16. Sica G, Vazquez MF, Altorki N et al. PAX-5 expression in pulmonary neuroendocrine neoplasms: its usefulness in surgical and fine-needle aspiration biopsy specimens. Am. J. Clin. Pathol. 2008; 129; 556-562.
17. Kanteti R, Nallasura V, Loganathan S et al. PAX5 is expressed in small-cell lung cancer and positively regulates c-met transcription. Lab. Invest. 2009; 89; 301-314.
18. Abiko K, Mandai M, Hamanishi J et al. Oct4 expression in immature teratoma of the ovary: relevance to histologic grade and degree of differentiation. Am. J. Surg. Pathol. 2010; 34; 1842-1848.